Like competitors Bennett X-Ray and Lorad, Fischer of Denver isdeveloping a full-view digital mammography system. In its RSNAbooth, the company for the first time will display a working prototypeof its full-view digital system and will show patient images
Like competitors Bennett X-Ray and Lorad, Fischer of Denver isdeveloping a full-view digital mammography system. In its RSNAbooth, the company for the first time will display a working prototypeof its full-view digital system and will show patient images acquiredwith a prototype installed at Thomas Jefferson University Hospitalin Philadelphia.
Fischer's prototype has a design similar to a standard mammographyunit, but it features a detector array more closely resemblingthat used on CT scanners, according to Anthony DeCarolis, vicepresident of sales and marketing. The array enables cliniciansto perform 3-D imaging of the breast. The array has a matrix of1024 x 1024, which results in a high-resolution image that canimprove visualization of minute calcifications, DeCarolis said.
Fischer will also display an improved Mammotest prone stereotacticbiopsy table, as well as enhancements in its MammoVision CCD cameratechnology used with its digital spot-film device. Fischer isworking on a CCD camera design that can be moved from the Mammotesttable to an upright mammography system to make digitally guidedstereotactic exams more convenient and affordable.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.